CR20200329A - Derivados de triazolopirimidina para usar como inhibidores de ghrelin o-acil transferasa (goat) - Google Patents

Derivados de triazolopirimidina para usar como inhibidores de ghrelin o-acil transferasa (goat)

Info

Publication number
CR20200329A
CR20200329A CR20200329A CR20200329A CR20200329A CR 20200329 A CR20200329 A CR 20200329A CR 20200329 A CR20200329 A CR 20200329A CR 20200329 A CR20200329 A CR 20200329A CR 20200329 A CR20200329 A CR 20200329A
Authority
CR
Costa Rica
Prior art keywords
ghrelin
goat
sup
acyl transferase
inhibitors
Prior art date
Application number
CR20200329A
Other languages
English (en)
Inventor
Viktor Vintonyak
Thomas Trieselmann
Christoph Hoenke
Cédrickx Godbout
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of CR20200329A publication Critical patent/CR20200329A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

<p>La presente invención se refiere a compuestos de la Fórmula general I, en donde los grupos R1 y R2 se definen de acuerdo con la reivindicación 1, que tienen propiedades farmacológicas valiosas, en particular, se fijan a ghrelin O-aciltransferasa (GOAT) y modulan su actividad. Los compuestos son adecuados para el tratamiento y la prevención de enfermedades que se pueden ver influenciadas por este receptor, tales como enfermedades metabólicas, en particular, obesidad.</p>
CR20200329A 2018-02-02 2019-01-28 Derivados de triazolopirimidina para usar como inhibidores de ghrelin o-acil transferasa (goat) CR20200329A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP18154831 2018-02-02
PCT/EP2019/051994 WO2019149660A1 (en) 2018-02-02 2019-01-28 Triazolopyrimidine derivatives for use as ghrelin o-acyl transferase (goat) inhibitors

Publications (1)

Publication Number Publication Date
CR20200329A true CR20200329A (es) 2020-09-04

Family

ID=61157054

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20200329A CR20200329A (es) 2018-02-02 2019-01-28 Derivados de triazolopirimidina para usar como inhibidores de ghrelin o-acil transferasa (goat)

Country Status (21)

Country Link
US (1) US11583532B2 (es)
EP (1) EP3746443B1 (es)
JP (1) JP7083397B2 (es)
KR (1) KR20200118125A (es)
CN (1) CN111683951B (es)
AU (1) AU2019215710A1 (es)
BR (1) BR112020014436A2 (es)
CA (1) CA3087925A1 (es)
CL (1) CL2020001909A1 (es)
CO (1) CO2020009177A2 (es)
CR (1) CR20200329A (es)
EA (1) EA202091803A1 (es)
EC (1) ECSP20050797A (es)
IL (1) IL276145A (es)
JO (1) JOP20200187A1 (es)
MA (1) MA51774A (es)
MX (1) MX2020007994A (es)
PE (1) PE20210658A1 (es)
PH (1) PH12020551170A1 (es)
SG (1) SG11202006302TA (es)
WO (1) WO2019149660A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6651054B2 (ja) 2016-08-05 2020-02-19 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング グレリンｏ−アシルトランスフェラーゼ（ｇｏａｔ）阻害薬として使用するためのオキサジアゾロピリジン誘導体
JP7083397B2 (ja) 2018-02-02 2022-06-10 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング グレリンｏ－アシルトランスフェラーゼ（ｇｏａｔ）阻害剤として使用するためのトリアゾロピリミジン誘導体
CA3087826A1 (en) 2018-02-02 2019-08-08 Boehringer Ingelheim International Gmbh Benzyl-, (pyridin-3-yl)methyl- or (pyridin-4-yl)methyl-substituted oxadiazolopyridine derivatives as ghrelin o-acyl transferase (goat) inhibitors
PH12022552277A1 (en) 2020-02-28 2024-03-04 Kallyope Inc Gpr40 agonists
CN121550230A (zh) 2020-03-26 2026-02-24 希诺皮亚生物科学公司 同位素标记的曲匹地尔衍生物
WO2021225969A1 (en) 2020-05-04 2021-11-11 Volastra Therapeutics, Inc. Imino sulfanone inhibitors of enpp1
PL4153600T3 (pl) 2020-05-22 2024-12-16 Boehringer Ingelheim International Gmbh Sposób ciągły wytwarzania 7-amino-5-metylo-[1,2,5]oksadiazolo[3,4- b]pirydynokarboksylanu alkilu
WO2021233882A1 (en) 2020-05-22 2021-11-25 Boehringer Ingelheim International Gmbh Process for manufacturing alkyl 7-amino-5-methyl-[1,2,5]oxadiazolo[3,4-b]pyridine-carboxylate
WO2021257614A1 (en) * 2020-06-16 2021-12-23 Volastra Therapeutics, Inc. Heterocyclic inhibitors of enpp1
CN115073363B (zh) * 2022-06-16 2024-01-26 宁波申泰生物科技有限公司 一种5-氟-2-甲氧基烟醛及其制备方法

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3338292A1 (de) * 1983-10-21 1985-05-02 Basf Ag, 6700 Ludwigshafen 7-amino-azolo(1,5-a)-pyrimidine und diese enthaltende fungizide
JP2002249492A (ja) 2000-12-22 2002-09-06 Nippon Bayer Agrochem Co Ltd トリアゾロピリミジン類
WO2004082383A1 (en) 2003-03-17 2004-09-30 Basf Aktiengesellschaft Use of triazolopyrimidines for combating nematode diseases of plants
EP1876899A2 (de) * 2005-04-25 2008-01-16 Basf Aktiengesellschaft Verwendung von 5-alkyl-6-phenylalkyl-7-amino-azolopyrimidinen, neue azolopyrimidine, verfahren zu ihrer herstellung und sie enthaltende mittel
JP6017754B2 (ja) 2007-02-15 2016-11-02 インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションＩｎｄｉａｎａ Ｕｎｉｖｅｒｓｉｔｙ Ｒｅｓｅａｒｃｈ Ａｎｄ Ｔｅｃｈｎｏｌｏｇｙ Ｃｏｒｐｏｒａｔｉｏｎ グルカゴン／ｇｌｐ−１受容体コアゴニスト
US8084454B2 (en) 2007-04-11 2011-12-27 Canbas Co., Ltd. Compounds with anti-cancer activity
AU2008245458B2 (en) 2007-04-30 2013-01-10 Abbvie Inc. Inhibitors of diacylglycerol O-acyltransferase type 1 enzyme
CA2687611A1 (en) 2007-05-24 2008-11-27 Bayer Schering Pharma Aktiengesellschaft Novel sulphoximine-substituted quinoline and quinazoline derivatives as kinase inhibitors
DK2158214T3 (da) 2007-06-15 2011-12-05 Zealand Pharma As Glukagonanaloger
FR2934058B1 (fr) 2008-07-15 2010-09-24 Centre Nat Rech Scient Dispositif de projection interferometrique a trois ouvertures pour produire une tache constituee de structures fines
FR2933989B1 (fr) 2008-07-16 2013-03-08 Commissariat Energie Atomique Procede de purification de microorganismes presents dans des echantillons liquides
FR2933975B1 (fr) 2008-07-17 2011-02-18 Servier Lab Nouveau procede de preparation de benzocyclobutenes fonctionnalises,et application a la synthese de l'ivabradine et de ses sels d'addition a un acide pharmaceutiquement acceptable.
NZ593813A (en) 2008-12-15 2013-02-22 Zealand Pharma As Glucagon analogues
JP5635531B2 (ja) 2008-12-15 2014-12-03 ジーランド ファーマ アクティーゼルスカブ グルカゴン類似体
JP5635529B2 (ja) 2008-12-15 2014-12-03 ジーランド ファーマ アクティーゼルスカブ グルカゴン類似体
WO2010070252A1 (en) 2008-12-15 2010-06-24 Zealand Pharma A/S Glucagon analogues
ME02220B (me) 2009-07-13 2016-02-20 Zealand Pharma As Analozi acilovanog glukagona
US20110078154A1 (en) 2009-09-28 2011-03-31 Accenture Global Services Gmbh Recruitment screening tool
WO2011114148A1 (en) 2010-03-17 2011-09-22 Astrazeneca Ab 4h- [1, 2, 4] triazolo [5, 1 -b] pyrimidin-7 -one derivatives as ccr2b receptor antagonists
AR081975A1 (es) 2010-06-23 2012-10-31 Zealand Pharma As Analogos de glucagon
EP2585482B1 (en) 2010-06-24 2019-03-27 Zealand Pharma A/S Glucagon analogues
SG11201403377QA (en) 2011-12-23 2014-07-30 Zealand Pharma As Glucagon analogues
JP6106179B2 (ja) 2012-02-24 2017-03-29 武田薬品工業株式会社 芳香環化合物
WO2013192388A1 (en) 2012-06-20 2013-12-27 University Of Virginia Patent Foundation Compositions and methods for regulating glucose homeostasis and insulin action
TWI608013B (zh) 2012-09-17 2017-12-11 西蘭製藥公司 升糖素類似物
UA118034C2 (uk) 2013-11-14 2018-11-12 Елі Ліллі Енд Компані Заміщений піперидилетилпіримідин як інгібітор грелін-o-ацилтрансферази
EP3193939A4 (en) 2014-09-17 2018-10-24 The Regents of The University of California Small lipopeptidomimetic inhibitors of ghrelin o-acyl transferase
WO2016123275A1 (en) 2015-01-30 2016-08-04 Boehringer Ingelheim International Gmbh Aldosterone synthase inhibitors
AR104672A1 (es) 2015-04-15 2017-08-09 Lilly Co Eli Inhibidores de grelina o-aciltransferasa
AR104673A1 (es) 2015-04-15 2017-08-09 Lilly Co Eli Inhibidores de grelina o-aciltransferasa
WO2017070680A1 (en) 2015-10-22 2017-04-27 Cavion Llc Methods for treating angelman syndrome and related disorders
JP6651054B2 (ja) 2016-08-05 2020-02-19 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング グレリンｏ−アシルトランスフェラーゼ（ｇｏａｔ）阻害薬として使用するためのオキサジアゾロピリジン誘導体
US10988487B2 (en) 2016-08-29 2021-04-27 Merck Sharp & Dohme Corp. Substituted n′-hydroxycarbamimidoyl-1,2,5-oxadiazole compounds as indoleamine 2,3-dioxygenase (IDO) inhibitors
WO2019149658A1 (en) 2018-02-02 2019-08-08 Boehringer Ingelheim International Gmbh Pyrazole- and indazole-substituted oxadiazolopyridine derivatives for use as ghrelin o-acyl transferase (goat) inhibitors
CR20200331A (es) 2018-02-02 2020-09-03 Boehringer Ingelheim Int Derivados de oxadiazolopirisdina sustituidos con heterociclilo para usar como inhibidores de ghrelin o-aciltrasferasa (goat)
CA3087826A1 (en) 2018-02-02 2019-08-08 Boehringer Ingelheim International Gmbh Benzyl-, (pyridin-3-yl)methyl- or (pyridin-4-yl)methyl-substituted oxadiazolopyridine derivatives as ghrelin o-acyl transferase (goat) inhibitors
JP7083397B2 (ja) * 2018-02-02 2022-06-10 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング グレリンｏ－アシルトランスフェラーゼ（ｇｏａｔ）阻害剤として使用するためのトリアゾロピリミジン誘導体

Also Published As

Publication number Publication date
CN111683951A (zh) 2020-09-18
IL276145A (en) 2020-09-30
EP3746443B1 (en) 2022-07-06
JP2021512115A (ja) 2021-05-13
US20210038603A1 (en) 2021-02-11
JP7083397B2 (ja) 2022-06-10
PH12020551170A1 (en) 2021-05-31
CO2020009177A2 (es) 2020-07-31
EA202091803A1 (ru) 2020-12-16
KR20200118125A (ko) 2020-10-14
CN111683951B (zh) 2023-10-13
AU2019215710A1 (en) 2020-07-23
JOP20200187A1 (ar) 2020-07-29
EP3746443A1 (en) 2020-12-09
US11583532B2 (en) 2023-02-21
WO2019149660A1 (en) 2019-08-08
CL2020001909A1 (es) 2020-10-30
BR112020014436A2 (pt) 2020-12-01
CA3087925A1 (en) 2019-08-08
MX2020007994A (es) 2020-09-09
ECSP20050797A (es) 2020-09-30
MA51774A (fr) 2021-05-12
SG11202006302TA (en) 2020-07-29
PE20210658A1 (es) 2021-03-31

Similar Documents

Publication Publication Date Title
CR20200329A (es) Derivados de triazolopirimidina para usar como inhibidores de ghrelin o-acil transferasa (goat)
MY197064A (en) Oxadiazolopyridine derivatives for use as ghrelin o-acyl transferase (goat) inhibitors
MX2020008116A (es) Derivados de oxadiazolopiridina sustituidos con heterociclilo para usar como inhibidores de ghrelin o-aciltransferasa (goat).
MX2020008053A (es) Derivados de oxadiazolopiridina sustituidos con bencilo, (piridin-3-il)metilo o (piridin-4-il)metilo como inhibidores de ghrelin o-aciltransferasa (goat).
MX2022001295A (es) Inhibidores de kif18a.
PH12020551208A1 (en) Compounds for the treatment of kinase-dependent disorders
PH12020550881A1 (en) Substituted bicyclic heterocyclic compounds as prmt5 inhibitors
JOP20200086B1 (ar) مشتقات إيميدازول مكثفة بها استبدال بمجموعات هيدروكسي ثلاثية كمثبطات لـ pi3k-جاما
MX2013012776A (es) Inhibidores de la tirosina cinasa de bazo que contienen aminopiridina.
PH12020551390A1 (en) AMINOPYRAZINE DIOL COMPOUNDS AS PI3K-y INHIBITORS
EA201592033A1 (ru) 3-(2-АМИНОПИРИМИДИН-4-ИЛ)-5-(3-ГИДРОКСИПРОПИНИЛ)-1H-ПИРРОЛО[2,3-c]ПИРИДИНОВЫЕ ПРОИЗВОДНЫЕ В КАЧЕСТВЕ ИНГИБИТОРОВ NIK ДЛЯ ЛЕЧЕНИЯ РАКА
EA033236B1 (ru) Новые производные пиразола в качестве ингибиторов nik
TN2016000511A1 (en) 1, 3, 4-thiadiazole compounds and their use in treating cancer
MX2022014351A (es) Compuestos para el tratamiento de trastornos dependientes de cinasas.
MX2020001531A (es) Nuevos compuestos hetorociclicos como inhibidores de cdk8/19.
ZA202107777B (en) Voruciclib polymorphs and methods of making and using thereof
TN2017000254A1 (en) Fumagillol derivatives
MX2023001906A (es) Diarilureas como moduladores alostericos de cannabinoide cb1.
MX2020010015A (es) Combinacion que comprende inhibidor de hdac y agonista de cd137 para la terapia del cancer.
EA201891687A1 (ru) Новые замещённые производные цианиндолина в качестве nik- ингибиторов